Study shows that Isconova´s Matrix-M is an excellent pandemic influenza vaccine candidate

Uppsala, Sweden, November 23 2009 - At a time like this, when the global society is under a pandemic influenza threat, the need for a safe, effective and antigen dose-sparing adjuvant becomes critical.Isconova announced today that a group at the Influenza centre, the Gade Institute at University of Bergen shows much encouraging performance of a new vaccine adjuvant (Isconova´s Matrix M) in a pandemic (H5N1) influenza vaccine adjuvant study [1]. The Matrix-M adjuvant stimulates a strong immune response against influenza virus with a high quality antibody response that also neutralise related